西西河

主题:【整理/讨论】mRNA疫苗有效性,及新冠死亡周期性 -- 铁手

共:💬103 🌺699 🌵2
全看分页树展 · 主题 跟帖
家园 续:今天中国Meheco和辉瑞签约在华销售Paxlovid

和中国哪个公司签不重要,重要的是一定会有公司签。而且在中国放开后大量阳性情况下,必然是“顺理成章”。辉瑞的mRNA疫苗估计也是必然了。美国市场不够了,中国市场来。凑巧不凑巧?

摘要下面的英文报导:

辉瑞说今年可以实现120M(M:百万)产量,到11月30止,共向52个国家销售37M。(自注:6个月后来看在中国的销量)。

美国政府宣布增加购买 3.7M,约$2B(B:十亿)。

辉瑞今年营收预期超过 $100B,其中一半以上来自新冠相关(包括疫苗)。

消息之前,有股市分析预测 Paxlovid 2022年销售 $22B,2023年 $12B(自注:也就是说,本来预期2023年的使用量会有大量下降。再注:Paxlovid 到目前为止的使用量,相对疫苗而言,并不高。此次签约后,2023年还会是 $12B?下次季报再来看。大概在2023年2月6 - 2月10)

以下路透社报导的部分内容。

Pfizer last year said it could produce up to 120 million courses of Paxlovid this year. As of Nov. 30, Pfizer had shipped almost 37 million courses of Paxlovid to 52 countries around the world, it said in a statement.

The U.S. government announced a deal on Tuesday to buy an additional 3.7 million Paxlovid courses for nearly $2 billion, supplementing the 20 million courses already purchased by the United States.

Pfizer, which also sells the COVID-19 vaccine it developed with German partner BioNTech SE, is expected to top $100 billion in revenue this year, more than half projected to come from its COVID business.

Prior to announcement of the new U.S. contract, analysts had forecast Paxlovid sales would top $22 billion in 2022 and be close to $12 billion next year, according to Refinitiv data.

通宝推:潜望镜,愣头兔,
全看分页树展 · 主题 跟帖


有趣有益,互惠互利;开阔视野,博采众长。
虚拟的网络,真实的人。天南地北客,相逢皆朋友

Copyright © cchere 西西河